Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan
Shipra Maheshwari,Ryan D. Gentzler
DOI: https://doi.org/10.21037/jtd-24-279
2024-10-01
Journal of Thoracic Disease
Abstract:Shipra Maheshwari, Ryan D. Gentzler Division of Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA Comment on: Shimokawa T, Okamoto H, Machida R, et al . Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Lung Cancer 2023;181:107195. Keywords: Small-cell lung cancer (SCLC); carboplatin; irinotecan; etoposide; immunotherapy Submitted Feb 21, 2024. Accepted for publication Sep 10, 2024. Published online Sep 23, 2024. doi: 10.21037/jtd-24-279 Small-cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma characterized by loss of tumor suppressors RB1 and TP53, activation of MYC, and increased Notch signaling which results in rapid tumor growth and early metastatic spread (1). With 250,000 new cases and 200,000 deaths annually, SCLC makes up about 15% of total lung cancers globally (2,3). Most patients diagnosed with SCLC are current or past heavy smokers (1). SCLC afflicts more men than women, reflecting tobacco use trends (3). The proportion of elderly patients over age 70 years with SCLC has increased in the last 35 years, from 23% in 1975 to 44% in 2010 (4). Approximately two-thirds of patients are diagnosed with extensive stage disease (ES-SCLC) on presentation. Extensive stage disease is defined as disease that cannot be treated within one radiation field or disease with distant metastases (5). Targetable mutations in kinase genes are uncommon, unlike in non-small cell lung cancer (NSCLC) in which biologic therapies can be effective (5). However, SCLC can be classified into biologically distinct subtypes based on transcription factors: ASCL1, NEUROD1, POU2F3, and YAP1 or inflamed subtype SCLC-I, the latter of which may be more susceptible to immunotherapy treatment (6). For decades, platinum plus etoposide was the standard of care for ES-SCLC. Although there is an initial high rate of response to chemotherapy, that response is not durable and resistance to chemotherapy inevitably develops, leading to a median overall survival (OS) of less than one year. Numerous trials comparing platinum/etoposide to cyclophosphamide/doxorubicin/vincristine (CAV), cyclophosphamide/epirubicin/vincristine (CEV), doxorubicin/cyclophosphamide/etoposide (ACE), and carboplatin/pemetrexed did not show alternative treatment superiority, maintaining platinum/etoposide as the treatment of choice (7). In Japan, cisplatin/irinotecan (CDDPI) is considered to be an acceptable first-line treatment for SCLC in younger patients (7). In the JCOG9511 phase II clinical trial comparing the use of CDDPI to cisplatin/etoposide (CDDPE) in 154 patients age 70 years and younger, the median OS was 12.8 months in the CDDPI group versus 9.4 months in the CDDPE group (P=0.002) and the landmark survival rate was 58.4% and 37.7% at one year, respectively (8). Confirmatory trials done outside of Japan did not show superiority of CDDPI to CDDPE (7). A meta-analysis on randomized trials for ES-SCLC demonstrated that platinum/irinotecan minimally improved OS over platinum/etoposide while examining four Western population trials [hazard ratio (HR) =0.87; P=0.02] with significantly more diarrhea, but less hematologic toxicity (9). In the current clinical trial, Shimokawa et al. sought to determine the efficacy of carboplatin/irinotecan (CI) versus carboplatin/etoposide (CE) in an elderly population of Japan residents (age 71 years and older) given the success of CI in a younger Japanese population (10). Immunotherapy has changed the landscape of SCLC treatment as it works to boost the activity of T cells against cancer cells by blocking programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) (3). Given that SCLC tends to have a high tumor mutational burden, it stimulates a robust T-cell response, making immunotherapy effective (PD-L1 inhibitors in particular). While the addition of immunotherapy to chemotherapy in the treatment of SCLC has improved OS compared to chemotherapy given alone, the benefit remains modest (11,12). Two phase III trials, IMpower133 and CASPIAN, showed improved OS with the addition of anti-PD-L1 immunotherapy to chemotherapy for ES-SCLC and both trials led to approvals of chemotherapy plus immunotherapy regimens, which are now considered standard of care in both the United States and Japan. IMpower133 was a multinational study that randomized 403 patients with ES-SCLC in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four cycles followed by maintenance with atezolizumab or placebo based on what they received in induction (11). Thirty-five point three percent in the atezolizumab arm and 36.6% of patients in the placebo arm were betwe -Abstract Truncated-
respiratory system